Liquidia Corp
About Liquidia Corp
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $158.3M
- Net income
- -$68.9M
- Total assets
- $327.9M
- Market cap
- $5.5B
- Operating margin
- -32.5%
- Net margin
- -43.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $158.3M
- Operating expenses
- $209.7M
- Operating income
- -$51.4M
- Income tax
- $0
- Net income
- -$68.9M
- EPS (basic)
- $-0.80
- EPS (diluted)
- $-0.80
Balance sheet
- Total assets
- $327.9M
- Current assets
- $273.4M
- Total liabilities
- $283.2M
- Current liabilities
- $135.8M
- Shareholders’ equity
- $44.7M
Cash flow
- Operating cash flow
- -$35.7M
- Investing cash flow
- -$6.3M
- Financing cash flow
- $59.7M
- Net cash flow
- $17.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.5B
- EPS (diluted)
- $-0.8
- Shares outstanding
- 86.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 26, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $68.9M in FY2025.
- Revenue grew 1132% from FY2021 to FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Liquidia Corp.
Write a review
News about Liquidia Corp
News & sentiment via Polygon.io
